Immunocore Holdings plc (NASDAQ:IMCR) Position Cut by Marshall Wace LLP

Marshall Wace LLP lowered its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 85.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,610 shares of the company's stock after selling 170,833 shares during the quarter. Marshall Wace LLP owned approximately 0.06% of Immunocore worth $844,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of IMCR. State Street Corp boosted its holdings in Immunocore by 63.9% during the third quarter. State Street Corp now owns 76,671 shares of the company's stock worth $2,387,000 after buying an additional 29,897 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Immunocore by 25.0% during the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock valued at $17,007,000 after acquiring an additional 109,206 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Immunocore by 125.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company's stock valued at $1,463,000 after buying an additional 27,598 shares during the period. Crossmark Global Holdings Inc. increased its holdings in shares of Immunocore by 36.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company's stock worth $1,121,000 after buying an additional 10,217 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of Immunocore by 17.3% in the 4th quarter. Legal & General Group Plc now owns 136,875 shares of the company's stock worth $4,038,000 after buying an additional 20,163 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IMCR has been the subject of several research analyst reports. JPMorgan Chase & Co. dropped their price target on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, April 14th. Mizuho decreased their price objective on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. Needham & Company LLC reissued a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research note on Thursday, April 10th. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Finally, Morgan Stanley restated an "equal weight" rating and set a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $59.44.

Insider Transactions at Immunocore

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of Immunocore stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the transaction, the director now directly owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. This trade represents a 60.40 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.40% of the company's stock.

Immunocore Stock Down 1.7 %

NASDAQ:IMCR traded down $0.51 during mid-day trading on Tuesday, reaching $30.12. The stock had a trading volume of 10,250 shares, compared to its average volume of 289,554. The stock's 50 day simple moving average is $28.83 and its two-hundred day simple moving average is $30.24. Immunocore Holdings plc has a 1-year low of $23.15 and a 1-year high of $62.22. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -31.70 and a beta of 0.75. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.